|
Jun 3
|
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in Recurrence-Free Survival & Distant Metastasis-Free Survival Versus KEYTRUDA in Patients With High-Risk Stage...
|
|
Jun 3
|
Is Moderna Stock a Buy Now That It's a 2-Product Company?
|
|
Jun 3
|
Moderna Investors Just Got Some Bullish News
|
|
Jun 3
|
FDA approves Moderna’s RSV vaccine mRESVIA
|
|
May 31
|
Moderna Scores FDA Approval For Its Second Product - Respiratory Syncytial Virus Vaccine
|
|
May 31
|
Moderna Gets FDA Approval For Respiratory Syncytial Virus Vaccine for Seniors
|
|
May 31
|
Top Midday Stories: SQM, Codelco to Mine Lithium; Moderna Gets Approval for RSV Vaccine; Tesla Recalls Over 100,000 Cars; Icahn Amasses Stake in Caesars
|
|
May 31
|
Moderna Looks for Boost From Newly Approved RSV Shot
|
|
May 31
|
Moderna Wins FDA Approval For Second-Ever Product; Why Its RSV Vaccine Could Dominate Pfizer, GSK
|
|
May 31
|
Moderna Receives U.S. FDA Approval for RSV Vaccine mRESVIA(R)
|
|
May 31
|
Moderna wins FDA approval for RSV vaccine
|
|
May 14
|
Is This a Setback for Moderna?
|
|
May 13
|
Moderna (MRNA) Falls as FDA Extends Review Time for RSV Vaccine
|
|
May 13
|
While shareholders of Moderna (NASDAQ:MRNA) are in the black over 5 years, those who bought a week ago aren't so fortunate
|
|
May 13
|
Company News For May 13, 2024
|
|
May 13
|
Investors Heavily Search Moderna, Inc. (MRNA): Here is What You Need to Know
|
|
May 13
|
Bull Market and Beyond: 2 Stocks Just Waiting to Soar
|
|
May 13
|
Moderna to Present at Upcoming Conferences in May/June 2024
|
|
May 12
|
Moderna and OpenAI Are Teaming Up, but Does That Make the Stock a Buy?
|
|
May 10
|
Novavax stock doubles after Sanofi deal marks 'new chapter' for company
|